Expectant management of localized prostate cancer.
Khan
Masood A
MA
James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Partin
Alan W
AW
Carter
H Ballentine
HB
D000230:Adenocarcinoma / Q000097:blood / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood; D002454:Cell Differentiation; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D008017:Life Expectancy; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D010166:Palliative Care; D018579:Patient Selection; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D016019:Survival Analysis; D019564:Unnecessary Procedures
D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen